A Study of BGM0504 Injection in Participants with Obesity or Overweight

NCT06704581 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

620

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight or Obesity

Interventions

DRUG: 5 mg BGM0504 injection
DRUG: 10 mg BGM0504 injection administered subcutaneously (SC) once a week
DRUG: 15 mg BGM0504 injection
DRUG: BGM0504 placebo

Sponsor

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.